Health Care • Biotechnology: Pharmaceutical Preparations
$1.76 ▼ -0.60
(-25.42%)
MKT CAP: $7.8M • VOL: 490.6K
52W L $2 52W H $3
ROARABLE / RQD
E • 32/100
PIOTROSKI
1 / 9
KPRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $16.0M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$12.8M | $4.5M | -$12.6M |
| Operating Margin % | — | 28.2% | — |
| Net Income (GAAP) | -$10.8K | $3.6K | -$12.5K |
| EBITDA (Normalized) | -$12.7M | $4.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.0M | $8.6M | -$9.6M |
| Capital Expenditures (CapEx) | $110.8K | $6.3K | — |
| Free Cash Flow (FCF) | -$10.1M | $8.6M | -$9.6M |
| FCF Margin % | — | 53.4% | — |
| Return on Invested Capital (ROIC %) | -45.0% | 16.2% | — |
| Cash & Short-Term Equivalents | $8.7M | $3.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $16.1M | $25.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KPRX.